vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and 1ST SOURCE CORP (SRCE). Click either name above to swap in a different company.

1ST SOURCE CORP is the larger business by last-quarter revenue ($113.1M vs $57.6M, roughly 2.0× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 8.7%). 1ST SOURCE CORP produced more free cash flow last quarter ($58.1M vs $-167.0M).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

1st Source Corporation is a financial services company headquartered in South Bend, Indiana. It operates 1st Source Bank, a bank with 81 branches in Indiana and Michigan. The bank's Specialty Finance Group provides financing for aircraft, trucks, and construction equipment. 1st Source Insurance provides insurance products and services.

PHAT vs SRCE — Head-to-Head

Bigger by revenue
SRCE
SRCE
2.0× larger
SRCE
$113.1M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+85.4% gap
PHAT
94.1%
8.7%
SRCE
More free cash flow
SRCE
SRCE
$225.1M more FCF
SRCE
$58.1M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PHAT
PHAT
SRCE
SRCE
Revenue
$57.6M
$113.1M
Net Profit
$40.0M
Gross Margin
86.7%
Operating Margin
45.4%
Net Margin
35.3%
Revenue YoY
94.1%
8.7%
Net Profit YoY
71.6%
6.5%
EPS (diluted)
$1.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
SRCE
SRCE
Q1 26
$113.1M
Q4 25
$57.6M
$110.8M
Q3 25
$49.5M
$110.7M
Q2 25
$39.5M
$108.2M
Q1 25
$28.5M
$104.0M
Q4 24
$29.7M
$97.8M
Q3 24
$16.4M
$97.9M
Q2 24
$7.3M
$97.3M
Net Profit
PHAT
PHAT
SRCE
SRCE
Q1 26
$40.0M
Q4 25
$41.1M
Q3 25
$-30.0M
$42.3M
Q2 25
$-75.8M
$37.3M
Q1 25
$-94.3M
$37.5M
Q4 24
$31.4M
Q3 24
$-85.6M
$34.9M
Q2 24
$-91.4M
$36.8M
Gross Margin
PHAT
PHAT
SRCE
SRCE
Q1 26
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Operating Margin
PHAT
PHAT
SRCE
SRCE
Q1 26
45.4%
Q4 25
Q3 25
-30.8%
49.7%
Q2 25
-151.7%
44.5%
Q1 25
-276.5%
45.8%
Q4 24
Q3 24
-433.0%
46.3%
Q2 24
-1055.4%
49.1%
Net Margin
PHAT
PHAT
SRCE
SRCE
Q1 26
35.3%
Q4 25
37.1%
Q3 25
-60.5%
38.2%
Q2 25
-191.9%
34.5%
Q1 25
-330.7%
36.1%
Q4 24
32.1%
Q3 24
-523.3%
35.7%
Q2 24
-1248.6%
37.8%
EPS (diluted)
PHAT
PHAT
SRCE
SRCE
Q1 26
$1.63
Q4 25
$1.67
Q3 25
$-0.41
$1.71
Q2 25
$-1.05
$1.51
Q1 25
$-1.31
$1.52
Q4 24
$1.27
Q3 24
$-1.32
$1.41
Q2 24
$-1.56
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
SRCE
SRCE
Cash + ST InvestmentsLiquidity on hand
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$-438.2M
$1.3B
Total Assets
$259.1M
$9.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
SRCE
SRCE
Q1 26
Q4 25
$130.0M
Q3 25
$135.2M
Q2 25
$149.6M
Q1 25
$212.3M
Q4 24
$297.3M
Q3 24
$334.7M
Q2 24
$276.2M
Total Debt
PHAT
PHAT
SRCE
SRCE
Q1 26
Q4 25
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Stockholders' Equity
PHAT
PHAT
SRCE
SRCE
Q1 26
$1.3B
Q4 25
$-438.2M
$1.3B
Q3 25
$-422.5M
$1.2B
Q2 25
$-405.8M
$1.2B
Q1 25
$-338.4M
$1.2B
Q4 24
$-253.6M
$1.1B
Q3 24
$-187.1M
$1.1B
Q2 24
$-233.8M
$1.0B
Total Assets
PHAT
PHAT
SRCE
SRCE
Q1 26
$9.1B
Q4 25
$259.1M
$9.1B
Q3 25
$240.3M
$9.1B
Q2 25
$250.2M
$9.1B
Q1 25
$294.2M
$9.0B
Q4 24
$378.3M
$8.9B
Q3 24
$387.0M
$8.8B
Q2 24
$319.4M
$8.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
SRCE
SRCE
Operating Cash FlowLast quarter
$-166.8M
$59.1M
Free Cash FlowOCF − Capex
$-167.0M
$58.1M
FCF MarginFCF / Revenue
-290.0%
51.4%
Capex IntensityCapex / Revenue
0.4%
0.9%
Cash ConversionOCF / Net Profit
1.48×
TTM Free Cash FlowTrailing 4 quarters
$-328.9M
$361.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
SRCE
SRCE
Q1 26
$59.1M
Q4 25
$-166.8M
$223.1M
Q3 25
$-14.1M
$51.0M
Q2 25
$-62.7M
$44.9M
Q1 25
$-84.9M
$71.8M
Q4 24
$-266.8M
$193.9M
Q3 24
$-63.6M
$68.4M
Q2 24
$-70.7M
$50.0M
Free Cash Flow
PHAT
PHAT
SRCE
SRCE
Q1 26
$58.1M
Q4 25
$-167.0M
$213.0M
Q3 25
$-14.1M
$47.3M
Q2 25
$-62.8M
$43.0M
Q1 25
$-84.9M
$69.3M
Q4 24
$-266.9M
$181.5M
Q3 24
$-63.6M
$66.7M
Q2 24
$-70.8M
$46.4M
FCF Margin
PHAT
PHAT
SRCE
SRCE
Q1 26
51.4%
Q4 25
-290.0%
192.2%
Q3 25
-28.6%
42.7%
Q2 25
-159.0%
39.8%
Q1 25
-297.9%
66.6%
Q4 24
-899.8%
185.5%
Q3 24
-389.0%
68.1%
Q2 24
-966.2%
47.7%
Capex Intensity
PHAT
PHAT
SRCE
SRCE
Q1 26
0.9%
Q4 25
0.4%
9.1%
Q3 25
0.1%
3.4%
Q2 25
0.2%
1.7%
Q1 25
0.1%
2.4%
Q4 24
0.5%
12.6%
Q3 24
0.3%
1.7%
Q2 24
0.6%
3.7%
Cash Conversion
PHAT
PHAT
SRCE
SRCE
Q1 26
1.48×
Q4 25
5.42×
Q3 25
1.21×
Q2 25
1.20×
Q1 25
1.91×
Q4 24
6.17×
Q3 24
1.96×
Q2 24
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons